1 – 17 of 17
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
The Porto European Cancer Research Summit 2021
(
- Contribution to journal › Article
- 2017
-
Mark
Assessment of value for resource allocation in cancer care
(
- Contribution to journal › Article
-
Mark
Comparator Report on Patient Access to Cancer Medicines in Europe Revisited - A UK Perspective
2017) In IHE report(
- Book/Report › Report
-
Mark
Societal challenges of precision medicine : Bringing order to chaos
(
- Contribution to journal › Article
- 2016
-
Mark
Drug utilization research in the area of cancer drugs
2016) p.315-327(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
The cost and burden of cancer in the European Union 1995–2014
(
- Contribution to journal › Article
-
Mark
Comparator report on patient access to cancer medicines in Europe revisited
2016) In IHE report(
- Book/Report › Report
- 2015
-
Mark
Insights into cancer surveillance in Central and Eastern Europe, Israel and Turkey
(
- Contribution to journal › Article
- 2014
-
Mark
Access to high-quality oncology care across Europe
2014) In IHE report(
- Book/Report › Report
-
Mark
Audio-recorded information to patients considering participation in cancer clinical trials - a randomized study
(
- Contribution to journal › Article
-
Mark
A Catalyst for Change: The European Cancer Patient's Bill of Rights.
2014) In The Oncologist(
- Contribution to journal › Article
- 2013
-
Mark
Målriktad behandling av bröstcancer
2013)(
- Other contribution › Miscellaneous
-
Mark
Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel
(
- Contribution to journal › Article
- 2006
-
Mark
Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401.
(
- Contribution to journal › Article
-
Mark
Basoluminal carcinoma: A new biologically and prognostically distinct entity between basal and luminal breast cancer
(
- Contribution to journal › Article
- 2000
-
Mark
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer : a randomised trial
(
- Contribution to journal › Article
- 1994
-
Mark
Metabolism of estrone sulfate by normal breast tissue : Influence of menopausal status and oral contraceptives
(
- Contribution to journal › Article